Expected Moves

Expected pivotal trial data presentation for key oncology combination therapies, assessing efficacy and out-licensing potential.

Q3 2026 earnings announcement focusing on sequential margin stabilization and pipeline commercialization execution.

Outcomes of China's National Reimbursement Drug List (NRDL) negotiations, dictating pricing for newly approved therapies.

Assessment of evolving U.S. healthcare supply chain policies and potential tariff impacts on Chinese biopharma out-licensing.

Full-year 2026 results and forward 2027 guidance, highlighting free cash flow generation and potential capital returns.